Advances in understanding HD pathogenesis have revealed novel therapeutic targets that could offer potential treatments. One such target is the excitotoxicity pathway. Excessive activation of excitatory neurotransmitters, particularly glutamate, leads to neuronal damage in HD. NMDA receptor antagonists, such as memantine, have shown neuroprotective effects in animal models and are being explored in clinical trials for HD.
Another emerging target is neuroinflammation. Inflammatory processes play a significant role in HD progression, contributing to neurodegeneration. Modulating the immune response using anti-inflammatory drugs or targeting specific inflammatory pathways has shown promise in preclinical studies, with potential to attenuate disease progression.
Additionally, the role of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), is being investigated. BDNF is crucial for neuronal survival and plasticity, and its levels are reduced in HD.
Huntington's Disease Treatment Therapies aimed at increasing BDNF expression, such as histone deacetylase inhibitors, hold promise in ameliorating disease symptoms. The treatment landscape for Huntington's disease is undergoing a significant transformation with the emergence of new strategies targeting the underlying genetic and molecular mechanisms of the disease. Gene therapy approaches, such as siRNA and ASOs, hold potential for directly reducing mutant HTT protein levels.
Huntington's Disease Treatment Market Research Report: by drug type (tetrabenazinedeutetrabenazine, chlorpromazine and others), Treatment (symptomatic therapy, disease-modifying therapy), End-users (hospital and others) - Forecast Till 2027Market Highlights:Huntington Disease is a brain disorder that causes uncontrolled movements, emotional problems, and loss of thinking ability.
Early symptoms can include irritability, depression, small involuntary movements, poor coordination, and trouble learning new information or making decisions.
The individuals suffering from this disorder may have trouble in walking, speaking, and swallowing.
People with this disorder also experience decline in thinking and reasoning abilities.
Individuals suffering with this huntington disease usually live about 15 to 20 years after signs and symptoms begin.Huntington’s disease treatment market is expected to grow in the near future due to rise in incidence of genetic diseases, increasing research and development activities to develop drugs that can be used for treatment of this disorder and developing healthcare sector.
Key players in market are making their position in many developing countries due to the FDI policies regulated within the pharmaceuticals industry in such countries with increasing consumer demands towards maintaining aesthetic appearance is also driving the market for global huntington’s disease treatment market.However, some factors that can hamper the growth of this market are rising side effect associated with drugs, lack of awareness regarding genetic disorder and alternative treatment plan.
